secwatch.observer — SEC 8-K summary
======================================

Issuer:     NGM BIOPHARMACEUTICALS INC (—)
CIK:        0001426332
Form:       8-K
Filed at:   2023-04-04T23:59:59+00:00
Accession:  0001628280-23-010574
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NGM Biopharmaceuticals lays off 75 employees, CSO resigns; cash runway extended to Q2 2025
--------------------------------------------------------------------------------

- Workforce reduced by 75 (~33% of headcount); restructuring charges estimated at $5M (majority in Q2 2023).
- Founder and CSO Jin-Long Chen resigns, effective Apr 4; Dan Kaplan appointed as new CSO.
- Company expects existing cash to fund operations into Q2 2025 (extended cash runway).
- Restructuring includes separation packages (≥3 months salary, healthcare through July, outplacement).
- Restructuring driven by difficulty raising capital after CATALINA trial data did not support financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426332/000162828023010574/0001628280-23-010574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426332/000162828023010574/ngm-20230403.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-010574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer